Acquisition of Patent on a composition for the prevention and/or treatment of acute respiratory viruses and rotavirus infections

 

 

OraTicx oral probiotics acquired a Patent on a composition for the prevention and/or treatment of acute respiratory viruses and rotavirus infections has been registered at the Korean Intellectual Property Office on the 4th of October, 2022. 

 

The present invention relates to a pharmaceutical composition for the prevention and treatment of upper respiratory tract infectious virus diseases, containing a supernatant of a lactic acid bacteria fermentation solution of oraCMS1 (Weisella cibaria CMS1) as an active ingredient.

 

Consumption of cell-free supernatant of the lactic acid bacteria fermentation of this invention not only suppresses the growth and biofilm of typical upper respiratory infections such as purulent streptococcus, staphylococcus, and pneumococcus, but also prevents and treats acute respiratory diseases.

 

Patent Number: 10-2451861

Patentee: Orapharm, Inc